U.S. Markets closed

European Commission Approves Puma Biotechnology’s Nerlynx

Daniel Collins
European Commission Approves Puma Biotechnology’s Nerlynx

On September 4, the European Commission approved the marketing authorization of Puma Biotechnology’s Nerlynx as extended adjuvant therapy for the treatment of adults with early-stage HER2-positive (hormone receptor-2 positive) breast cancer who completed previous adjuvant trastuzumab-containing therapy less than a year ago.